Introduction {#S1}
============

Follicular helper T cells (Tfh) are key regulators of germinal center (GC) formation and T cell-dependent long-term humoral immunity. They provide crucial signals to B lymphocytes in GCs and guide high-affinity, isotype-switched, antibody responses, and memory B cell development ([@B1]).

Follicular helper T cells express the transcriptional repressor BCL6, considered as the critical master regulator of their development *in vivo* ([@B2], [@B3]) and are the major source of IL-21, which is necessary for IgG class-switch recombination and antibody-affinity maturation ([@B4]).

The differentiation of Tfh cells is considered as a multistage process starting in the T cell zone of secondary lymphoid organs. Here, T lymphocytes engage in cognate interaction and ICOS-ICOSL signaling with dendritic cells (DCs). These signals promote expression of CXCR5, allowing Th cells to relocalize at the T--B border zone where they receive additional signals from B cells ([@B5], [@B6]). This second wave of interactions further stabilizes Tfh cell fate---characterized by a high expression of BCL6 and surface markers such as CXCR5, PD1, ICOS---and results in the migration toward GCs and the delivery of optimal helper signals to B cells ([@B5]--[@B7]).

This stepwise differentiation pathway results from the sequential activation of a series of transcription factors regulating distinct phases of the Tfh developmental program. Within this intricate Tfh-associated transcriptional network, Ascl2 and BCL6 represent master regulators initiating Tfh cell development by inducing the expression of key Tfh-associated genes while inhibiting the expression of other, non-Tfh, helper cell subset signature genes ([@B2], [@B3], [@B8], [@B9]).

The transcription factor c-Maf, belonging to the AP-1 family of basic region/leucine zipper factor, is highly expressed by mature Tfh cells, and is thought to mainly regulate the expression of cytokines able to promote B cell proliferation and differentiation. Indeed, c-Maf is expressed downstream of Batf and ICOS signaling and has been shown to transactivate IL-4 and IL-21 promoters ([@B10]--[@B12]). In particular, Sahoo et al. recently reported that c-Maf promotes IL-4 secretion in Tfh cells through both direct binding to the CNS2 region in the *il4* locus and via induction of IRF4, thus revealing a distinct role of c-Maf in IL-4 secretion between Th2 and Tfh cell subsets ([@B12]).

Collectively, the available literature posits c-Maf as an important regulator of cytokine production in Tfh cells, thus acting at a later stage of the Tfh developmental program ([@B1], [@B10], [@B12]). To directly evaluate the putative role of c-Maf in the generation and regulation of Tfh activity, we have characterized the immune response of mice selectively lacking c-Maf expression in the T cell compartment. In contrast to our expectations, T cells lacking c-Maf expression failed to acquire expression of key Tfh markers (such as BCL6, CXCR5, and PD1), indicating an important, and non-redundant role for c-Maf in the initiation of Tfh cell development. Accordingly, mice lacking c-Maf in the T cell compartment displayed reduced secretion of high-affinity antibodies. Our data thus uncover a major and unsuspected role for c-Maf in regulating Tfh cell development and T-cell-dependent humoral responses.

Materials and Methods {#S2}
=====================

Mice and Immunization {#S2-1}
---------------------

C57BL/6 mice were purchased from Envigo (Horst, The Netherlands). c-Maf-flox mice ([@B13]) were kindly provided by Dr. Carmen Birchmeier (Max Delbrück Center for Molecular Medicine, Berlin, Germany) and were back-crossed for nine generations to C57BL/6 in our animal facility before breeding with CD4-CRE mice ([@B14]), provided by Dr. Geert Van Loo (University of Gent, Gent, Belgium) to generate T-cell compartment-specific c-Maf-deficient mice (c-Maf^KO-T^ mice). CD3ε-KO mice were from EMMA (CDTA, Orleans, France).

All mice were used at 6--12 weeks of age.

Mice were immunized by injecting 10 μg keyhole limpet hemocyanin (KLH, Calbiochem) in foot pads (f.p.) along with Alum (1 mg/f.p., Thermo Fisher Scientific, Rockford, IL, USA) or IFA (sigma; 25 μL/f.p.) supplemented with LPS (*Escherichia coli* serotype 0111:B5, Calbiochem; 5 μg/f.p.). In some experiments, mice were immunized intra-peritoneally (i.p.) with 75 μg nitrophenyl-KLH (NP~25~-KLH, Biosearch Technologies, Novato, CA, USA) and 1 mg of Imject Alum. When indicated, mice were further boosted on day 14 by a second immunization with NP-KLH in saline.

Differentiation of BMDCs {#S2-2}
------------------------

Bone marrow cells were collected from naive mice and grown for 8 days in RPMI supplemented with 10% FCS, 1% [l]{.smallcaps}-glutamine, 1% sodium pyruvate, 0.1% 2-ME, 50 μg/mL streptomycin, 50 IU/mL penicillin, and 20 ng/mL recombinant murine GM-CSF (provided by Pr. Kris Thielemans, Medical School of the Vrije Universiteit Brussel). At day 8, bone marrow-derived dendritic cells (BMDCs) were pulsed with 30 μg/mL KLH in the presence of 1 μg/mL LPS. At day 9, BMDCs were collected and injected in recipient mice (5 × 10^5^ cells/f.p.).

Antibody Detection {#S2-3}
------------------

Serum levels of NP-specific antibodies were determined by enzyme-linked immunosorbent assay (ELISA) according to standard procedures. Briefly, ELISA plates were coated with 2 μg/ml NP-BSA and incubated with serial dilutions of sera in duplicate wells. Bound antibodies were revealed using peroxidase-coupled anti-mouse isotype-specific rat monoclonal antibodies (Synabs sa, Louvain-la Neuve, Belgium) followed by the peroxidase substrate tetramethylbenzidine (Life Technologies). A solution of 2 N H~2~SO~4~ was used to quench the reaction, and optical densities were quantified at 450 nm. ODs were converted to units based on a standard curve made from a previously available immunized serum arbitrarily defined at 1,000 U ml^−1^.

The relative affinities of NP-immune sera were calculated by comparing their binding to differently haptenised carrier proteins (heavily haptenised NP~18~-BSA versus lightly haptenised NP~2~-BSA; Biosearch Technologies, Inc.), as described ([@B15]). The same serial dilutions of each serum sample were allowed to bind on NP~18~-BSA and NP~2~-BSA. The relative affinities of the anti-NP serum antibodies are expressed as a ratio of the serum volumes required to give the 50% of maximum binding on NP~18~-BSA divided by the volumes required for same binding on NP~^2^~-BSA (serum relative affinity = vol~50%\ binding~ on NP~^18^~-BSA/vol~50%\ binding~ on NP~2~-BSA).

Flow Cytometry {#S2-4}
--------------

Specific cell-surface staining was performed using a standard procedure with anti-CD4, anti-PD1, anti-IgD, anti-GL7 (eBioscience), and anti-CXCR5 mAbs (BD Biosciences).

Intracellular c-Maf, GATA-3, FoxP3, BCL6, Ki67 (Ab from BD Biosciences), and T-bet (eBioscience), staining was performed according to the manufacturer's protocol (FoxP3 staining set protocol, eBioscience). Cells were analyzed by flow cytometry with a FACS Canto II (BD Biosciences) and analyzed with the FlowJo Software. Live cells were analyzed within a FSC-A/FSC-H gate to exclude cell doublets and triplets.

Differentiation of Th Cells *In Vitro* and B-Cell Help Assay {#S2-5}
------------------------------------------------------------

CD62L^hi^CD4^+^ T cells and B cells were purified from naive animals by magnetic separation, as previously described ([@B16], [@B17]). The percentage of purified cell fractions in all experiments ranged between 90 and 98%, as estimated by flow cytometry (data not shown). Naive CD62L^hi^CD4^+^ T cells (5 × 10^5^ cells/well in 24-well plates) were activated for 48--72 h with plastic-coated anti-CD3 mAb (5 μg/mL) and soluble anti-CD28 mAb (1 μg/mL). Th1 cells were differentiated by the addition of recombinant IL-12 (10 ng/mL) and anti-IL-4 mAb (10 μg/mL), and Th2 polarization was initiated by the addition of IL-4 (10 ng/mL) and anti-interferon-γ (IFN-γ) mAb (10 μg/mL). Th17 and Tfh cells were differentiated in media containing IL-6 (20 ng/mL) and supplemented (Th17) or not (Tfh) with TGF-β (3 ng/mL), in the presence of anti-IL-4 and anti-IFN-γ mAbs.

Serial dilutions of *in vitro*-derived Tfh cells were co-cultured for 7 days with syngeneic naïve B cells (5 × 10^4^ cells/well) in the presence of anti-CD3 mAbs (500 ng/mL). T cells were irradiated (2,000 cGy) before the beginning of the coculture with B cells to prevent their outgrowth during the 7-day culture. IgG1 antibodies in the supernatants were determined by ELISA, using rat monoclonal anti-mouse isotype antibodies, as described ([@B18]) (Synabs, capture antibody loMG1.13; detection antibody loMK.1). Purified mouse IgG1 (BD Biosciences) was used as standard reference.

Bone Marrow Chimeras {#S2-6}
--------------------

Recipient CD3ε-KO mice were lethally irradiated with 2 × 600 rad and reconstituted with a 1:1 mixture of bone marrow from congenic wild type CD45.1^+^ and c-Maf^KO-T^ (CD45.2^+^) mice (2 × 10^6^ cells of each). Chimeric mice were immunized with KLH/Alum 8 weeks after reconstitution.

Peyer's Patches Isolation {#S2-7}
-------------------------

Peyer's patches (PPs) were cut from the small intestine and incubated for 20 min at 37°C in Hank's balanced salt solution (HBSS) containing 400 U/mL collagenase (Worthington, Lakewood, NJ, USA). PPs were next dissociated in HBSS/EDTA solution to generate a single-cell suspension for flow cytometry staining.

Real-time Quantitative RT-PCR {#S2-8}
-----------------------------

RNA was extracted using the TRIzol method (Invitrogen) and reverse transcribed with Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Quantitative real-time RT-PCR was performed using the SYBR Green Master mix kit (ThermoFisher). Primer sequences were as follow: RPL32 (F) ACATCGGTTATGGGAGCAAC; RPL32 (R) TCCAGCTCCTTGACATTGT; IL-4 (F) ATGCACGGAGATGGATGTG; IL-4 (R) AATATGCGAAGCACCTTGGA; IL-17A (F) ATCCCTCAAAGCTCAGCGTGTC; IL-17A (R) GGGTCTTCATTGCGGTGGAGAG; IL-21 (F) GCCAGATCGCCTCCTGATTA; IL-21 (R) CATGCTCACAGTGCCCCTTT; IFNγ (F) TGCCAAGTTTGAGGTCAACA; IFNγ (R) GAATCAGCAGCGACTCCTTT.

Statistical Analysis {#S2-9}
--------------------

Differences between groups were analyzed with the Mann--Whitney test for two-tailed data. A *p*-value less than 0.05 was considered as significant.

Results {#S3}
=======

c-Maf Is Expressed in Early Tfh Cells during *In Vivo* Vaccination Settings and Is Required for Tfh Cell Development {#S3-1}
--------------------------------------------------------------------------------------------------------------------

Keyhole limpet hemocyanin/Alum vaccination promotes the *in vivo* differentiation of cells expressing key Tfh-associated markers including PD1, CXCR5, and BCL6 by 72 h, gradually increasing till day 5 (Figures [1](#F1){ref-type="fig"}A--D and data not shown). Kinetic analysis revealed that c-Maf was already expressed in the very few early Tfh found in the draining lymph nodes of day 3-vaccinated mice (Figure [1](#F1){ref-type="fig"}E). Although some c-Maf expression could be detected in the non-Tfh cell subset, higher levels of c-Maf were strongly associated with the Tfh cell compartment at any time points (Figures [1](#F1){ref-type="fig"}E--J). Moreover, c-Maf expression strongly correlated with BCL6 expression, therefore suggesting a time-coordinated expression pattern of these transcription factors throughout the Tfh cell differentiation process (Figures [1](#F1){ref-type="fig"}E--L).

![**Early expression of c-Maf during the course of follicular helper T cells (Tfh) cell differentiation**. WT mice were immunized by footpad injection of keyhole limpet hemocyanin in Alum. Draining lymph nodes were recovered on days 3--5 and analyzed for Tfh cell marker expression. Contour plots in **(A--D)** illustrate CXCR5 and PD1 staining profiles of CD4^+^ cells while contour plots in **(E--J)** represent BCL6 and c-Maf staining profiles of Tfh cells (CXCR5^+^ PD1^+^) and non-Tfh cells (CXCR5^−^ PD1^−^) gated as indicated in **(A--D)**; **(K,L)** histograms of c-Maf or BCL6 expression intensity (expressed as mfi, median fluorescence intensity) among Tfh and non-Tfh cell subsets. Results are representative of two independent experiments; histograms and numbers in **(A--D)** represent the mean ± SD of three individual mice.](fimmu-08-00480-g001){#F1}

To investigate the role of c-Maf in Tfh cell function and differentiation, we generated conditional KO mice in which *lox*P-flanked alleles of c-Maf (c-Maf^f/f^) are deleted by the Cre recombinase expressed from the CD4^+^ T-cell-specific *Cd4* promoter (c-Maf^f/f^-CD4^CRE^ mice, hereafter referred as c-Maf^KO-T^ mice). These mice showed normal T cell development *in vivo* (data not shown) and naïve c-Maf-KO Th cells underwent optimal Th1, Th2, or Th17 polarization *in vitro* (Figures [2](#F2){ref-type="fig"}A--C). Upon culture in Tfh-promoting conditions, c-Maf-KO T cells displayed a twofold reduction in IL-21 production (Figures [2](#F2){ref-type="fig"}D,E), in agreement with a role for c-Maf in regulating IL-21 production ([@B11]). Finally, c-Maf-deficient Tfh cells showed reduced ability to deliver B cell help for IgG1 secretion *in vitro* (Figure [2](#F2){ref-type="fig"}F).

![**c-Maf up-regulates IL-21 secretion and B-cell help capacity by follicular helper T cells (Tfh)-like cells *in vitro***. **(A--E)** Naïve T cells were purified from the spleen of C57BL/6 mice and stimulated for 2 days with anti-CD3/CD28 mAbs under Th0, Th1, Th2, Th17, or Tfh-like conditions. Gene expression relative to RPL32 mRNA of **(A)** interferon-γ, **(B)** IL-4, **(C)** IL-17, and **(D)** IL-21 was assessed by qRT-PCR. WT Th0 sample was set to 1. **(E)** Compilation of four independent experiments as in panel **(D)**: IL-21 expression in WT Tfh cells was set as 100. **(F)** Serial dilutions of Th0 and Tfh cells were incubated with purified B cells (5 × 10^5^ cells/well) and anti-CD3 mAbs (500 ng/ml). Culture supernatants were tested on day 7 for IgG1 content. Results are expressed as mean ± SD of duplicates **(A--D)** or four independent cultures **(F)** and are representative of at least two independent experiments. Differences between groups were analyzed with the Mann--Whitney test for two-tailed data. \**p* \< 0.05.](fimmu-08-00480-g002){#F2}

To assess the role of c-Maf in Tfh cell development, we immunized wild type and c-Maf^KO-T^ mice with KLH/Alum or KLH/IFA/LPS. The loss of c-Maf strongly inhibited the differentiation of Tfh cells independently of the adjuvant formulation used (Figures [3](#F3){ref-type="fig"}A--H). The percentage and overall numbers of Tfh cells (assessed by either CXCR5^+^ PD1^+^, CD4^+^ BCL6^+^, or CXCR5^+^BCL6^+^ T cells) were significantly decreased in c-Maf^KO-T^ mice (Figures [3](#F3){ref-type="fig"}B,C,E,F,H).

![**c-Maf is required for follicular helper T cells (Tfh) cell development**. **(A--H)** c-Maf^fl/fl^ and c-Maf^KO-T^ mice were immunized with keyhole limpet hemocyanin (KLH) in Alum **(A--F)** or KLH + LPS in IFA **(G,H)**. Draining lymph nodes were analyzed on day 7 for Tfh cells (defined as CXCR5^+^ PD1^+^, CD4^+^ BCL6^+^, or CXCR5^+^ BCL6^+^) among viable CD4^+^ cells. **(A,D,G)** show representative contour plots; histograms **(B,C,E,F,H)** represent the percentages, and absolute numbers of Tfh cells, as indicated. **(I--K)** Tfh (CXCR5^+^ PD1^+^) and total CD4 T cell expression in Peyer's patches of wild type and c-Maf^KO-T^ mice. Results represent the mean ± SD of four to five individual mice and are representative of at least three independent experiments **(B,C,E,F,H)** or are pooled from four independent experiments \[*n* = 11--13 **(J,K)**\]. Differences between groups were analyzed with the Mann--Whitney test for two-tailed data. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001.](fimmu-08-00480-g003){#F3}

Inhibition of Tfh cell development *in vivo* was already evidenced at early time points following immunization (days 2 and 4, Figure S1 in Supplementary Material) and did not result from a general impaired Th cell response as judged by the presence of proliferating T lymphocytes (as assessed by expression of the Ki67 marker, data not shown and Figures [4](#F4){ref-type="fig"}D,E) in the corresponding lymph nodes.

![**c-Maf promotes follicular helper T cells (Tfh) cell differentiation and counteracts Th1 and Th2 cell development**. WT mice were immunized by footpad injection of 5 × 10^5^ LPS-stimulated, KLH-pulsed bone marrow-derived dendritic cells derived from C57BL/6 mice. Draining LN cells were recovered on day 7 and analyzed for Tfh cell expression **(A--C)** and Ki67 proliferation marker expression **(D,E)** among viable CD4^+^ T cells or BCL6, RORγt, T-bet, and GATA-3 expression among CD4^+^Ki67^+^ cell gate **(F--I)**. Histograms represent the percentage or absolute numbers of Tfh among viable CD4^+^ T cell gate **(B,C,E)**, percentages of cells among CD4^+^Ki67^+^ cell gate **(J--M)**, or transcription factor expression intensity \[mfi **(N,O)**\]. Differences between groups were analyzed with the Mann--Whitney test for two-tailed data. \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](fimmu-08-00480-g004){#F4}

To test whether these observations were also applicable to non-vaccinal-driven Tfh responses, we analyzed the Tfh response that spontaneously occurs in the intestinal PP of mice harboring commensal microbiota. The proportion of Tfh cells among CD4^+^ cell in PP was severely reduced in c-Maf^KO-T^ mice (Figures [3](#F3){ref-type="fig"}I--K), suggesting that c-Maf expression in T cells was also essential for normal homeostatic Tfh cell responses.

c-Maf Promotes Tfh Cell Differentiation in a T-Cell Intrinsic Manner {#S3-2}
--------------------------------------------------------------------

To address the potential role of c-Maf in the regulation of Th cell responses *in vivo*, we immunized C57BL/6 mice with BMDCs loaded with KLH in the presence of LPS. We previously reported that this vaccination protocol leads to the coordinated upregulation of Tfh, Th1, Th2, and Th17 responses ([@B19], [@B20]). Analysis of the CD4^+^ T cell response further confirmed the defect in Tfh cell differentiation despite normal accumulation of CD4^+^Ki67^+^ cells in c-Maf^KO-T^ mice (Figures [4](#F4){ref-type="fig"}A--F,J). Notably, CD4^+^Ki67^+^ cells recovered from c-Maf^KO-T^ immunized mice expressed higher levels of T-bet or GATA-3, the major transcription factors associated with the Th1- or Th2-cell differentiation program, respectively (Figures [4](#F4){ref-type="fig"}H,I,L--O). As expected from the literature ([@B21]), c-Maf^KO-T^ mice failed to express optimal levels of RORγt following immunization (Figures [4](#F4){ref-type="fig"}G,K).

Overall, these observations point to a role for c-Maf in promoting Tfh and Th17 cell differentiation, while restraining the development of Th1 and Th2 lymphocytes upon antigen-stimulation *in vivo*.

We next generated chimeras by reconstituting irradiated CD3^−/−^ recipient mice with a 1:1 mixture of congenitally marked bone marrow cells from wild type (CD45.1^+^) and c-Maf^KO-T^ (CD45.2^+^) donor mice. Despite an equivalent proliferative response upon immunization (Figures [5](#F5){ref-type="fig"}A,B,E), cMaf-deficient CD4^+^ T cells displayed a reduced potential to acquire Tfh-features, both in the periphery (lymph nodes draining the immunization site, Figures [5](#F5){ref-type="fig"}C,D) and in the PP (Figure [5](#F5){ref-type="fig"}F), pointing to a cell-autonomous defect in the Tfh differentiation of c-Maf-deficient CD4^+^ T cells.

![**c-Maf induces follicular helper T cells (Tfh) cell differentiation in a T-cell intrinsic manner**. Flow cytometry of CD4^+^ T cells in the spleen of chimeras generated with a mixture of WT (CD45.1) and c-Maf^KO-T^ (CD45.2) bone marrow cells, assessed 7 days after immunization with keyhole limpet hemocyanin/Alum in f.p. **(A)** gating strategy to identify WT and c-Maf-KO CD4^+^ T cells in the chimeric mice; **(B,C)** representative contour plots of activation and Tfh markers in both WT and c-Maf-KO CD4^+^ T cell subsets; **(D,E)** summary of Tfh and activated cell frequency from **(B,C)**; **(F)** summary of Tfh cell frequency in Peyer's patches of chimeras. Each symbol represents individual mice. Results represent the mean ± SD of eight individual mice and are pooled from two independent experiments **(D,E)** or are representative of two independent experiments **(F)**. Paired Mann--Whitney test: \*\**p* \< 0.01; \*\*\**p* \< 0.001.](fimmu-08-00480-g005){#F5}

c-Maf Expression in T Cells Is Required for Optimal Humoral Responses {#S3-3}
---------------------------------------------------------------------

We next tested whether c-Maf deficiency in the T cell compartment would affect the development of humoral responses. The loss of c-Maf led to a strongly reduced GC B cell response in the draining lymph nodes of immunized mice (Figure [6](#F6){ref-type="fig"}A). Accordingly, NP-KLH/Alum immunized c-Maf^KO-T^ mice produced lower anti-NP IgG1 antibodies titers at all time points (primary to late secondary response) considered, whereas anti-NP IgM levels remained non-significantly affected (Figures [6](#F6){ref-type="fig"}B--D,F). In particular, mice lacking c-Maf expression in T cells failed to secrete detectable levels of high-affinity NP-specific IgG1 antibodies (Figures [6](#F6){ref-type="fig"}E,G,H), in keeping with the concept that c-Maf-signaling in T cells promotes Tfh cell development, thereby controlling both isotype switch and affinity maturation processes.

![**c-Maf is required for high-affinity antibody response**. **(A)** Control and c-Maf^KO-T^ mice were immunized with keyhole limpet hemocyanin (KLH)/Alum in fp and draining lymph node were analyzed on day 7. Contour plots and histograms represent B~GC~ cells (defined as IgD^low^-GL7^+^, among CD19^+^ B cell gate). **(B--H)** Mice were immunized ip with NP-KLH in Alum. Sera were collected at the indicated timings and tested for total \[fixation on NP~24~-BSA-coated enzyme-linked immunosorbent assay (ELISA) plates\] anti-NP IgG1 **(B,D,F)** and IgM **(C)**. High-affinity IgG1 were detected on NP~4~-BSA-coated ELISA plates **(E,G)**. Relative affinity is expressed as the ratio of serum volume corresponding to 50% binding on NP~24~-BSA and NP~4~-BSA **(H)**. Each symbol represents individual mice. Results are pooled from two independent experiments **(A)** or are representative of three independent experiments **(B--H)**. Difference between groups was analyzed with the Mann--Whitney test for two-tailed data. \*\**p* \< 0.01; \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001.](fimmu-08-00480-g006){#F6}

Discussion {#S4}
==========

While expression of cMaf has long been considered as a hallmark of Tfh cells, its precise role during Tfh cell development was unknown at the beginning of the present study. We demonstrate herein that c-Maf plays a major, non-redundant role in the differentiation of Tfh cells *in vivo*. c-Maf is expressed early during Tfh cell induction and mice harboring a T cell-specific conditional ablation of c-Maf are strongly impaired in their Tfh response to both antigen/adjuvant vaccinations and commensal intestinal bacteria.

By using retroviral ectopic expression of c-Maf or BCL6 in *in vitro*-derived human Tfh cells, Kroenke et al. first reported that c-Maf and BCL6 regulated distinct features of Tfh cell function, with BCL6 being critical for T cell positioning within the follicle and directing T--B interactions (through upregulation of CXCR5, CXCR4, CCR7, SAP, PD1, CD40L, ICOS, CXCL13) and c-Maf promoting and sustaining IL-21 secretion ([@B10]). The cooperation of c-Maf and BCL6/Ascl2 to achieve complete Tfh cell fate through orchestration of distinct sets of genes was further supported by studies indicating that c-Maf-bound genes hardly correlated with genes bound by BCL6 or Ascl2 ([@B8], [@B9]). Collectively, and in agreement with the well-known role of c-Maf in transactivating the IL-4 and IL-21 promoters ([@B11], [@B12]), these data suggested that c-Maf regulates Tfh cell function by fine-tuning cytokine production in Ascl2/BCL6-driven differentiated Tfh cells ([@B1]). Our data challenge this simple view of cMaf sustaining the Tfh program through cytokine, and in particular IL-21, production only. Indeed, c-Maf deficiency in the T cell compartment led to a virtually complete loss of Tfh cells, while lack of IL-21--IL-21R signaling appeared as largely compatible with Tfh cell development ([@B22]--[@B24]). Similarly, reduction in Tfh cell numbers was more severe in c-Maf^KO-T^ than in mice lacking STAT3 (the major IL-6/IL-21 signaling pathway in T cells) ([@B20], [@B22], [@B25]), thus suggesting that the defect observed in c-Maf^KO-T^ mice did not simply reflect a consequence of reduced IL-21 signaling in these cells.

Using a fetal liver transplant experiment, Bauquet et al. reported that loss of c-Maf resulted in markedly reduced numbers of Th17 and Tfh cells ([@B26]), suggesting that c-Maf might also regulate Tfh cell differentiation. However, the entire hematopoietic compartment (including T, B, and APCs) was defective for c-Maf in these chimeric mice, still leaving open the question of a direct intrinsic role of c-Maf in the Tfh cell differentiation program. In keeping with these conclusions, we provide evidence herein suggesting that c-Maf controls Tfh cell fate in a cell-autonomous fashion. Indeed, wild type Tfh cells failed to rescue Tfh differentiation of c-Maf-deficient T cells in chimeric mice, suggesting that soluble factors provided by wild type T cells cannot compensate for c-Maf loss during Tfh cell development.

As mentioned earlier, a first wave of pre-Tfh cell induction precedes the full Tfh cell differentiation process (characterized by stabilization of high levels of BCL6 expression) ([@B5]--[@B7]). Our *in vivo* studies reveal that c-Maf and BCL6 are co-expressed during this early step of Tfh cell development. Although previous studies and our own unpublished data have shown that over-expression of c-Maf does not directly induce BCL6 expression in Th cells ([@B8], [@B10]), we observe a severe defect in BCL6 expression in CD4^+^ Th cells, 1 week after immunization, in the absence of c-Maf. Collectively, these data thus suggest that promotion of the early wave of Tfh cell differentiation by c-Maf may facilitate further stabilization of BCL6 expression in fully committed Tfh cells.

*In vitro* studies confirmed that c-Maf expression was required for adequate IL-21 production ([@B11]). As previously documented, activation of naïve Th cells in the presence of IL-6 led to the differentiation of IL-21-producing Tfh-like cells able to induce B cell growth and antibody secretion ([@B17], [@B18]). Using the same *in vitro* assay, we observed a twofold reduction in IL-21 secretion by c-Maf-deficient Tfh-like cells, concomitantly with a reduced ability to deliver B cell help for antibody production in T--B co-culture assays. Thus, although failure to secrete adequate IL-21 levels may explain the reduced B cell help properties of c-Maf-deficient T cells *in vitro*, the strict requirement for c-Maf expression to achieve B cell help *in vivo* probably reflects additional roles for this transcription factor in driving Tfh development in a physiological setting.

The negative influence of c-Maf on Th2 responses may appear at odds with previous publications that led several groups to consider c-Maf as a prototypical Th2-transcription factor ([@B27], [@B28]). Notably, most of these studies were based on *in vitro* assays suggesting a positive role for c-Maf in regulating IL-4 promoter activity. However, Sato et al. later reported that c-Maf-transgenic memory T helper cells did not produce enhanced IL-4 levels when compared to WT cells, and that the expression of *Il4* was not reduced in immunodeficient mice reconstituted with c-Maf^−/−^ fetal liver transplants ([@B29]). In keeping with this last study, we observed an enhanced, rather than reduced, production of IL-4 by c-Maf-deficient T cells induced *in vivo* in response to antigen-pulsed DC vaccination. Similarly, c-Maf-deficient T cells displayed a marked Th1-like phenotype, further suggesting a possible role for c-Maf in controlling non-Tfh responses. These observations may suggest that similarly to BCL6, c-Maf may promote Tfh differentiation by limiting the acquisition of Th1/Th2 phenotypic traits. The identification of the precise mechanism whereby c-Maf may limit Th2 responses was beyond the scope of this study but might be related to limitation of GATA-3 expression in Th2 cells in our *in vivo* setting. Noteworthy, both GATA-3 and cMaf are involved in vertebrate lens development ([@B30]). Of interest, GATA-3 expression is strongly upregulated in c-Maf-deficient lens, a finding compatible with a negative role for c-Maf in regulating GATA-3 expression ([@B31]).

In conclusion, the fact that Tfh cell differentiation strongly relies on ICOSL/ICOS and IL-6/STAT3 signaling---two pathways known to induce expression of c-Maf ([@B18], [@B32]--[@B34])---strongly supports our findings indicating an important role for c-Maf in driving Tfh cell differentiation. The present study thus adds c-Maf to a lengthy list of transcription factors (including BCL6, Ascl2, TCF-1, Batf, STAT3, NFAT, and IRF4) that have been shown to play a major, non-redundant role in Tfh cell development ([@B1]). The identification of the relative roles of these transcription factors in initiating and maintaining Tfh cell represents therefore an important challenge requiring further studies.
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